Table 5.
Apolipoprotein E-adjusted estimates of the association of 5-hydroxytriptamine transporter gene-linked polymorphic region (5-HTTLPR) S-plus carriers with neuropsychiatric symptoms in patients with Alzheimer’s disease (AD) according to to the presence of delusion symptom
| All | AD-D | AD-noD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| p | OR | (95%CI) | p | OR | (95%CI) | p | OR | (95%CI) | |
| Hallucination | 0.600 | 0.835 | (0.412–1.700) | 0.480 | 1.436 | (0.529–3.900) | – | – | – |
| Agitation/aggression | 0.504 | 0.745 | (0.314–1.770) | 0.139 | 2.280 | (0.769–6.770) | 0.160 | 1.586 | (0.833–3.020) |
| Depressed mood | 0.580 | 0.727 | (0.236–2.240) | 0.561 | 0.674 | (0.178–2.540) | 0.611 | 1.960 | (1.480 × 10−1 - 2.610 × 101) |
| Anxiety | 0.216 | 0.498 | (0.166–1.500) | 0.582 | 0.681 | (0.174–2.670) | 0.610 | 1.730 | (2.110 × 10−1 - 1.427 × 101) |
| Euphoria | 0.970 | 0.992 | (0.631–1.560) | 0.570 | 1.210 | (0.628–2.330) | – | – | – |
| Apathy | 0.968 | 1.025 | (0.306–3.440) | 0.742 | 1.270 | (0.306–5.270) | 0.690 | 1.780 | (1.070 × 10−1 - 2.950 × 101) |
| Disinhibition | 0.490 | 1.006 | (0.990–1.020) | 0.390 | 1.010 | (0.987–1.030) | – | – | – |
| Irritability/liability | 0.883 | 0.928 | (0.344–2.510) | 0.054 | 3.520 | (0.988–12.500) | 0.280 | 1.505 | (0.720–3.150) |
| Aberrant motor activity | 0.050 | 1.692 | (1.004–2.850) | 0.013 | 2.257 | (1.195–4.260) | 0.550 | 1.407 | (0.461–4.300) |
| Sleep disturbances | 0.889 | 0.923 | (0.299–2.850) | 0.731 | 1.266 | (0.330–4.860) | 0.923 | 1.130 | (8.860 × 10−2 - 1.450 × 101) |
| Eating disorder | 0.464 | 1.476 | (0.521–4.180) | 0.801 | 1.161 | (0.364–3.710) | 0.514 | 2.380 | (1.780 × 10−1 - 3.186 × 101) |
AD-D AD patients with delusions, AD-noD AD patients without delusions, OR odds ratio, CI confidence interval;